Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PPID | Q08752 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213534 | 0.88 | ALDH1A1 (0.55) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL5941081 | 0.88 | PIN1 (0.56) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL691909 | 0.87 | SMN1; SMN2 (0.56) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL9686760 | 0.87 | PIN1 (0.53) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL3213531 | 0.85 | PIN1 (0.52) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL3211799 | 0.85 | PIN1 (0.52) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL15173708 | 0.85 | PIN1 (0.54) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL15173707 | 0.84 | PIN1 (0.53) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL22144166 | 0.83 | PIN1 (0.50) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB | |
| SCHEMBL3211795 | 0.83 | PIN1 (0.50) | PIN1ALDH1A1SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | PIN1 651/4885ALDH1A1 304/4885SMN1; SMN2 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.